Treats relapsing forms of multiple sclerosis (MS). ANDA 214022, held by Hybio. Glatiramer Acetate.
As of Nov 16, 2026, ANDA 214022 (Glatiramer Acetate), held by Hybio, was first approved by FDA on Feb 11, 2026, with 0 approved supplements and 0 published complete response letters.
Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 11, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Glatiramer Acetate40MG/ML · injectable;subcutaneous | Glatiramer Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters